SCHEMBL4594814

SCHEMBL4594814

Cc1cc2c(cc1C=O)OCO2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.59
HPGD P15428 1/20 0.59
ALDH1A1 P00352 8/20 0.47
MAPT P10636 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
HSD17B10 Q99714 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.42
GRIA1 P42261 1/20 0.41
GRIA2 P42262 1/20 0.41
GRIA3 P42263 1/20 0.41
GRIA4 P48058 1/20 0.41
ERN1 O75460 1/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MITF O75030 1/20 0.38
HSP90AA1 P07900 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL549278 0.88 HPGD (0.46) LMNAHPGDALDH1A1MAPTTDP1
SCHEMBL14070022 0.84 LMNA (0.64) LMNAHPGDALDH1A1MAPTTDP1
SCHEMBL4451990 0.78 LMNA (0.58) LMNAHPGDALDH1A1MAPTTDP1
SCHEMBL8005199 0.77 CYP3A4 (0.44) LMNAHPGDALDH1A1MAPTTDP1
SCHEMBL17821971 0.76 LMNA (0.40) LMNAHPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL17821970 0.76 LMNA (0.40) LMNAHPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL1128702 0.76 HPGD (0.56) LMNAHPGDALDH1A1MAPTTDP1
SCHEMBL31123847 0.76 HPGD (0.56) LMNAHPGDALDH1A1MAPTTDP1
SCHEMBL4134378 0.75 LMNA (0.55) LMNAHPGDALDH1A1MAPTTDP1
SCHEMBL22133239 0.75 LMNA (0.55) LMNAHPGDALDH1A1MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250025443-A1 COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES Clear Creek Bio, Inc. (US) 2025-01-23 US disclosed
US-20240300962-A1 Isoquinoline Derivatives, Methods of Synthesis and Uses Thereof PROSETTA BIOSCIENCES INC (US) 2024-09-12 US disclosed
US-12024521-B2 Isoquinoline derivatives, methods of synthesis and uses thereof PROSETTA BIOSCIENCES, INC. (US) 2024-07-02 US disclosed
US-11664093-B2 Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-05-30 US disclosed
WO-2023064493-A1 COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES Clear Creek Bio, Inc. (US) 2023-04-20 WO disclosed
WO-2023064493-A1 COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES Clear Creek Bio, Inc. (US) 2023-04-20 WO disclosed
EP-4149471-A1 ISOQUINOLINE DERIVATIVES, METHODS OF SYNTHESIS AND USES THEREOF Prosetta Biosciences, Inc. (US) 2023-03-22 EP disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
WO-2022006228-A1 ISOQUINOLINE DERIVATIVES, METHODS OF SYNTHESIS AND USES THEREOF PROSETTA BIOSCIENCES, INC. (US) 2022-01-06 WO disclosed
US-20210403477-A1 Isoquinoline Derivatives, Methods of Synthesis and Uses Thereof PROSETTA BIOSCIENCES, INC. 2021-12-30 US disclosed
US-20010014684-A1 THIENO-PYRIDINE SULFONAMIDES DERIVATIVES THEREOF AND RELATED COMPOUNDS THAT MODULATE THE ACTIVITY OF ENDOTHELIN ENCYSIVE PHARMACEUTICALS INC. 2001-08-16 US disclosed
US-6013655-A HYPOTENSIVE AGENTS; RESPIRATORY SYSTEM DIISORDERS TEXAS BIOTECHNOLOGY CORPORATION (US) 2000-01-11 US disclosed
EP-0898571-A1 THIENO-PYRIDINE SULFONAMIDES, DERIVATIVES THEREOF AND RELATED COMPOUNDS THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1999-03-03 EP disclosed
US-5804585-A INHIBIT BINDING OF ENDOTHELIN PEPTIDE TO ENDOTHELIN RECEPTORS TEXAS BIOTECHNOLOGY CORPORATION (US) 1998-09-08 US disclosed
WO-1997039000-A1 THIENO-PYRIDINE SULFONAMIDES, DERIVATIVES THEREOF AND RELATED COMPOUNDS THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1997-10-23 WO disclosed
US-5475024-A Useful in treating liver disease EISAI CO., LTD. (JP) 1995-12-12 US disclosed
US-5292901-A Benzodioxole derivatives EISAI CO., LTD. (JP) 1994-03-08 US disclosed
EP-0281098-B1 BENZODIOXOLE DERIVATIVES, COMPOSITIONS COMPRISING THE SAME, AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICAMENTS Eisai Co., Ltd. (JP) 1992-11-25 EP disclosed
US-5110956-A Liver disorders EISAI CO., LTD. (JP) 1992-05-05 US disclosed
EP-0281098-A1 Benzodioxole derivatives, compositions comprising the same, and the use of the same for the manufacture of medicaments Eisai Co., Ltd. (JP) 1988-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12024521-B2 Isoquinoline derivatives, methods of synthesis and uses thereof POLRMT, MAVS, SYNCRIP LMNA 772/4885HPGD 989/4885ALDH1A1 3238/4885
US-20210403477-A1 Isoquinoline Derivatives, Methods of Synthesis and Uses Thereof POLRMT, MAVS, SYNCRIP LMNA 772/4885HPGD 989/4885ALDH1A1 3238/4885
US-20240300962-A1 Isoquinoline Derivatives, Methods of Synthesis and Uses Thereof POLRMT, MAVS, SYNCRIP LMNA 772/4885HPGD 989/4885ALDH1A1 3238/4885
US-20010014684-A1 THIENO-PYRIDINE SULFONAMIDES DERIVATIVES THEREOF AND RELATED COMPOUNDS THAT MODULATE THE ACTIVITY OF ENDOTHELIN EDNRB, EDNRA, AGTR1 LMNA 2948/4885HPGD 968/4885ALDH1A1 4060/4885
US-20250025443-A1 COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES ACE, PREP, PEPD LMNA 627/4885HPGD 2322/4885ALDH1A1 2460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.